Heron Q1 2024 net product sales $34.7M (+17% YoY); net loss per share improves to $(0.02)

HERON THERAPEUTICS, INC. /DE/

2024-Q1 EPS reported -$0.02 revenue$34,670,000

Net product sales $34.7M vs $29.6M YoY; net loss per share $(0.02) vs $(0.27).
Gross margin improved to 76% in Q1 2024 from 43% in Q1 2023.
ZYNRELEF net sales $5.0M (+43% YoY); FDA expanded indication approved Jan 23, 2024, covering soft tissue and orthopedic procedures.
Reaffirmed FY2024 guidance: product revenues $138-158M, adjusted operating expenses $108-116M, adjusted EBITDA $(22)-$3M.
Partnership with CrossLink Life Sciences; 191 CrossLink sales reps trained and engaged with physicians.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HERON THERAPEUTICS, INC. /DE/ reported three months ended March 31, 2024 results: revenue Net Product Sales of $34.7 million, EPS Net Loss Per Share $(0.02). Guidance reaffirmed.

Period: three months ended March 31, 2024
Revenue: Net Product Sales of $34.7 million
EPS: Net Loss Per Share $(0.02)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-24-053963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.